PLX PHARMA INC (PLXP) Stock Price, Forecast & Analysis
USA - NASDAQ:PLXP - US72942A1079 - Common Stock
PLXP Key Statistics, Chart & Performance
The current stock price of PLXP is 0.087 USD. In the past month the price decreased by -43.51%. In the past year, price decreased by -97.52%.
PLXP Latest News, Press Relases and Analysis
PLXP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 42.04 | 874.88B | ||
| JNJ | JOHNSON & JOHNSON | 17.97 | 449.32B | ||
| MRK | MERCK & CO. INC. | 9.79 | 215.51B | ||
| PFE | PFIZER INC | 7.63 | 138.90B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.12 | 95.03B | ||
| ZTS | ZOETIS INC | 18.97 | 53.29B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.38 | 22.49B | ||
| VTRS | VIATRIS INC | 4.34 | 11.80B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.39 | 10.68B | ||
| CORT | CORCEPT THERAPEUTICS INC | 83.77 | 7.77B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.89B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 3.77B |
Related stock screener links
About PLXP
Company Profile
PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. The company is headquartered in Sparta, New Jersey and currently employs 16 full-time employees. The company went IPO on 2014-03-13. The firm has two commercialized products, VAZALORE 81 milligram (mg) and VAZALORE 325 mg, which are liquid-filled aspirin capsules for over the counter (OTC) distribution. The firm markets VAZALORE to the healthcare professional and the consumer through several sales and marketing channels. Its product pipeline also includes other oral NSAIDs using the PLxGuard drug delivery platform, including PL1200 Ibuprofen 200 mg and PL1100 Ibuprofen 400 mg, for pain and inflammation in Phase I clinical stage. PLxGuard drug delivery platform employs a pH-dependent release mechanism that relies on association of lipidic excipients with APIs for targeted release in the GI tract.
Company Info
PLX PHARMA INC
9 Fishers Ln Ste E
Sparta NEW JERSEY 07871 US
CEO: Natasha Giordano
Employees: 16
Phone: 17138421249.0
PLX PHARMA INC / PLXP FAQ
Can you describe the business of PLX PHARMA INC?
PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. The company is headquartered in Sparta, New Jersey and currently employs 16 full-time employees. The company went IPO on 2014-03-13. The firm has two commercialized products, VAZALORE 81 milligram (mg) and VAZALORE 325 mg, which are liquid-filled aspirin capsules for over the counter (OTC) distribution. The firm markets VAZALORE to the healthcare professional and the consumer through several sales and marketing channels. Its product pipeline also includes other oral NSAIDs using the PLxGuard drug delivery platform, including PL1200 Ibuprofen 200 mg and PL1100 Ibuprofen 400 mg, for pain and inflammation in Phase I clinical stage. PLxGuard drug delivery platform employs a pH-dependent release mechanism that relies on association of lipidic excipients with APIs for targeted release in the GI tract.
What is the stock price of PLX PHARMA INC today?
The current stock price of PLXP is 0.087 USD. The price decreased by -27.8% in the last trading session.
What is the dividend status of PLX PHARMA INC?
PLXP does not pay a dividend.
What is the ChartMill technical and fundamental rating of PLXP stock?
PLXP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Would investing in PLX PHARMA INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PLXP.
Is PLX PHARMA INC (PLXP) expected to grow?
The Revenue of PLX PHARMA INC (PLXP) is expected to decline by -57.24% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the employee count for PLXP stock?
PLX PHARMA INC (PLXP) currently has 16 employees.
PLXP Technical Analysis
PLXP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PLXP. PLXP has a bad profitability rating. Also its financial health evaluation is rather negative.
PLXP Financial Highlights
Over the last trailing twelve months PLXP reported a non-GAAP Earnings per Share(EPS) of -1.02. The EPS increased by 68.03% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
PLXP Forecast & Estimates
6 analysts have analysed PLXP and the average price target is 11.22 USD. This implies a price increase of 12796.55% is expected in the next year compared to the current price of 0.087.
For the next year, analysts expect an EPS growth of 36.14% and a revenue growth -57.24% for PLXP